Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27368384 | 0.76 | IDO1 (0.32) | IDO1PLAU | |
| SCHEMBL30030411 | 0.76 | IDO1 (0.32) | IDO1PLAU | |
| SCHEMBL27459327 | 0.72 | — | — | |
| SCHEMBL28023171 | 0.72 | MAPT (0.32) | ALDH1A1PLAUKDM4EGAA | |
| SCHEMBL16486471 | 0.71 | MAPT (0.34) | LMNAALDH1A1PLAUTSHRKDM4E | |
| SCHEMBL8595371 | 0.70 | — | — | |
| SCHEMBL8595375 | 0.70 | — | — | |
| SCHEMBL7247395 | 0.68 | KDM4E (0.41) | LMNAPOLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL1096641 | 0.68 | MAOA (0.36) | LMNAPOLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL28072453 | 0.67 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | GLAZIER ARNOLD | 2007-07-26 | — | — | US | disclosed |
| EP-1409017-A4 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | DRUG INNOVATION & DESIGN INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1636197-A1 | NOVEL 3-SUBSTITUTED-1,4-BENZODIAZEPINES | Aston University (GB) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106310-A1 | NOVEL 3-SUBSTITUTED-1,4-BENZODIAZEPINES | ASTON UNIVERSITY (GB) | 2004-12-09 | — | — | WO | disclosed |
| EP-1409017-A2 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | Drug Innovation & Design, Inc. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | DRUG INNOVATION & DESIGN, INCORPORATED | 2003-02-13 | — | — | US | disclosed |
| WO-2003000201-A2 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | DRUG INNOVATION & DESIGN, INCORPORATED (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| US-4296239-A | Amino-4H-s-triazolo[4,3-a][1,4]benzodiazepines | THE UPJOHN COMPANY (US) | 1981-10-20 | — | — | US | disclosed |
| US-4180668-A | Piperidino-4H-s-triazolo[4,3-a][1,4]benzodiazepines | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | NOS2 2457/4885ADORA3 943/4885LMNA 4027/4885 |
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | CCKBR, CCKAR, GABRB1 | NOS2 4155/4885ADORA3 160/4885LMNA 4248/4885 |
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | EPHA2, EEA1, TPX2 | NOS2 4859/4885ADORA3 2344/4885LMNA 4102/4885 |
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | EPHA2, EEA1, HAVCR2 | NOS2 4853/4885ADORA3 2241/4885LMNA 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.